[go: up one dir, main page]

WO1999036105A3 - Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune - Google Patents

Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune Download PDF

Info

Publication number
WO1999036105A3
WO1999036105A3 PCT/US1999/000857 US9900857W WO9936105A3 WO 1999036105 A3 WO1999036105 A3 WO 1999036105A3 US 9900857 W US9900857 W US 9900857W WO 9936105 A3 WO9936105 A3 WO 9936105A3
Authority
WO
WIPO (PCT)
Prior art keywords
igm
cancer
therapy
autoimmune disease
monoclonal igm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000857
Other languages
English (en)
Other versions
WO1999036105A2 (fr
WO1999036105A9 (fr
Inventor
Paul E Borchardt
Huibert M Vriesendorp
Syed M Quadri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MCA DEVELOPMENT BV
MCA DEV BV
Original Assignee
MCA DEVELOPMENT BV
MCA DEV BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MCA DEVELOPMENT BV, MCA DEV BV filed Critical MCA DEVELOPMENT BV
Priority to EP99917293A priority Critical patent/EP1047457A2/fr
Priority to JP2000539876A priority patent/JP2002509122A/ja
Priority to CA002318231A priority patent/CA2318231A1/fr
Priority to AU35445/99A priority patent/AU3544599A/en
Publication of WO1999036105A2 publication Critical patent/WO1999036105A2/fr
Publication of WO1999036105A9 publication Critical patent/WO1999036105A9/fr
Publication of WO1999036105A3 publication Critical patent/WO1999036105A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

On a trouvé que l'on pouvait utiliser de grands agrégats d'anticorps ou des molécules telles que l'immunoglobuline M, l'immunoglobuline G conjuguée ou les protéines de fusion de l'immunoglobuline G pour traiter des tumeurs par administration intra-compartimentale ou intratumorale d'un anticorps antitumoral couplé à une toxine. Le traitement convient également contre certains troubles caractérisés par le dépôt d'un complexe immun, et notamment la polyarthrite rhumatoïde. Selon la réalisation préférée, l'anticorps est l'immunoglobuline M, et la toxine est un radio-isotope, et de façon plus préférentielle une immunoglobuline M radiomarquée par le 111In ou le 90Y. Les exemples mettent en évidence l'efficacité sur des modèles murins.
PCT/US1999/000857 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune Ceased WO1999036105A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99917293A EP1047457A2 (fr) 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune
JP2000539876A JP2002509122A (ja) 1998-01-16 1999-01-15 癌および自己免疫疾患のための治療における放射性標識化モノクローナルＩｇＭの使用
CA002318231A CA2318231A1 (fr) 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune
AU35445/99A AU3544599A (en) 1998-01-16 1999-01-15 Use of radiolabeled monoclonal igm in therapy for cancer and autoimmune disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US862098A 1998-01-16 1998-01-16
US09/008,620 1998-01-16

Publications (3)

Publication Number Publication Date
WO1999036105A2 WO1999036105A2 (fr) 1999-07-22
WO1999036105A9 WO1999036105A9 (fr) 1999-10-21
WO1999036105A3 true WO1999036105A3 (fr) 2000-02-10

Family

ID=21732655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000857 Ceased WO1999036105A2 (fr) 1998-01-16 1999-01-15 Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune

Country Status (5)

Country Link
EP (1) EP1047457A2 (fr)
JP (1) JP2002509122A (fr)
AU (1) AU3544599A (fr)
CA (1) CA2318231A1 (fr)
WO (1) WO1999036105A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240120B2 (en) * 2001-01-29 2008-05-08 Biogen Idec Inc. Modified antibodies and methods of use
WO2002096948A2 (fr) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Anticorps tetravalents modifies et procedes d'utilisation
TW200510532A (en) * 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
US20070212346A1 (en) 2003-10-09 2007-09-13 Tomoyuki Igawa Highly Concentrated Stabilized Igm Solution
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
EP2803355A1 (fr) * 2007-10-09 2014-11-19 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Laminin-1 à utiliser dans l'amélioration de la régénération musculaire après une blessure ou pour améliorer la cicatrisation si administré de façon systémique
KR102289054B1 (ko) * 2019-03-29 2021-08-19 한국수력원자력 주식회사 저선량방사선에 의한 류마티스 관절염 예방

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015625A1 (fr) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPIE UTILISANT UNE EMISSION DE PARTICULES $g(a)
WO1993017707A1 (fr) * 1992-03-04 1993-09-16 Akzo N.V. PRE-CIBLAGE DE PAIRE DE LIAISON $i(IN VIVO)
US5583219A (en) * 1989-05-26 1996-12-10 Akzo Nobel N.V. Macrocyclic chelating agent
WO1997044461A2 (fr) * 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583219A (en) * 1989-05-26 1996-12-10 Akzo Nobel N.V. Macrocyclic chelating agent
WO1990015625A1 (fr) * 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPIE UTILISANT UNE EMISSION DE PARTICULES $g(a)
WO1993017707A1 (fr) * 1992-03-04 1993-09-16 Akzo N.V. PRE-CIBLAGE DE PAIRE DE LIAISON $i(IN VIVO)
WO1997044461A2 (fr) * 1996-05-22 1997-11-27 Novopharm Biotech, Inc. Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Ph. D Thesis", 1997, THE UNIVERSITY OF TEXAS H.S.C. AT HOUSTON GRAD. SCH. OF BIOMED. SCI, HOUSTON, US *
BENACH J L ET AL: "A MURINE IGM MONOCLONAL ANTIBODY BINDS AN ANTIGENIC DETERMINANT IN OUTER SURFACE PROTEIN A, AN IMMUNODOMINANT BASIC PROTEIN OF THE LYME DISEASE SPIROCHETE", JOURNAL OF IMMUNOLOGY, vol. 140, no. 1, 1 January 1988 (1988-01-01), pages 265 - 272, XP002001274 *
BORCHARDT P.E. ET AL: "Intralesional radiolabeled human monoclonal IgM in human tumor xenografts", RADIOTHERAPY AND ONCOLOGY, 1997, VOL. 44, NO. 3, PAGE(S) 283-293, XP002112294 *
BORCHARDT PE ET AL: "Indium-111- and yttrium-90- labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.", J NUCL MED, MARCH 1998, VOL. 39, NO. 3, PAGE(S) 476-484, XP002112298 *
DATABASE DISSERTATION ABSTRACTS University Microflims International; BORCHARDT, PAUL ERIC: "RADIOLABELED HUMAN MONOCLONAL IGM FOR INTRACOMPARTMENTAL CANCER THERAPY (RADIOIMMUNOTHERAPY, INDIUM, YTTRIUM, LYMPHOMAS)", XP002112299 *
DISSERTATION ABSTRACTS INTERNATIONAL, vol. 58, no. 08 part B, 1997, pages 4177 *
QUADRI S M: "Intraperitoneal In-111 and Y - 90 labeled human IgM ( AC6C3 -2B12) in nude mice with peritoneal carcinomatosis of a human cancer.", JOURNAL OF NUCLEAR MEDICINE, 1995, VOL. 36, NO. 5, PAGE(S) 160P, XP002112295 *
QUADRI, SYED M. ET AL: "Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis", J. NUCL. MED., 1996, VOL. 37, NO. 9, PAGE(S) 1545-1551, XP002112297 *
QUADRI, SYED M. ET AL: "Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12", CANCER RES., 1995, VOL. 55, NO. 23, SUPPL., PAGE(S) 5736S-5742S, XP002112296 *
RIVA P ET AL: "LOCOREGIONAL IMMUNOTHERAPY OF HUMAN OVARIAN CANCER: PRELIMINARY RESULTS", INTERNATIONAL JOURNAL OF RADIATION APPLICATIONS AND INSTRUMENTATION PART B: NUCLEAR MEDICINE AND BIOLOGY, vol. 16, no. 6, 1 January 1989 (1989-01-01), pages 659 - 666, XP000054551 *
WATANABE N ET AL: "Preparation of Yttrium-90-Labeled Human Macroaggregated Albumin for Regional Radiotherapy", NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 5, 1 July 1997 (1997-07-01), pages 465-469, XP004085841 *

Also Published As

Publication number Publication date
JP2002509122A (ja) 2002-03-26
EP1047457A2 (fr) 2000-11-02
CA2318231A1 (fr) 1999-07-22
WO1999036105A2 (fr) 1999-07-22
AU3544599A (en) 1999-08-02
WO1999036105A9 (fr) 1999-10-21

Similar Documents

Publication Publication Date Title
EG15882A (en) Procede de preparation de nouveaux conjuges associants,par liaison covalente,une enzyme et un anticorps
HU9502711D0 (en) Antibody-conjugates with antitumor effect and method of preparation thereof
EP0765172A4 (fr) Anticorps monoclonaux croises se liant specifiquement a la selectine e et a la selectine p
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
LU90854I2 (fr) Anticorps monoclonal chim-rique humain - murine qui se lie avec une haute affinit- - la fois - la forme soluble et - la forme transmembranaire de tnf-a mais pas - la lymphotoxine-a (tnf-beta) ou un sel ou d-riv- pharmaceutiquement acceptable de celui-ci en particulier un ester un -ther un sulfate un carbonate un glucuronide en particulier l'infliximab
MX9804358A (es) Apoptosis inducida por el anticuerpo monoclonal anti-her2.
ZA912036B (en) Catalytic antibody components
EP0220065A3 (en) Trichothecene conjugates
GB9009548D0 (en) Chimeric antibody and method
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
BR0316779A (pt) Anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptìdeo isolado, formulação lìquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
EP0939653A4 (fr) Humanisation d'un anticorps anti-idiotype dirige contre un antigene carcino-embryonnaire et utilisation en tant que vaccin anti-tumoral et pour cibler un emplacement
ATE233102T1 (de) Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
WO1999036105A3 (fr) Immunoglobuline m monoclonale radiomarquee destinee au traitement du cancer et d'une maladie auto-immune
SI1684770T1 (sl) Oligo-beta-(1,3)-glukan in monoklonska protitelesa proti raku
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
WO2002100343A3 (fr) Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine-3 a utiliser dans le traitement du cancer
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
JPS62181224A (ja) 両親媒性分子による抗体物質の処理方法
Yao et al. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment
Matzku et al. Detachment of cell surface-bound anticarcinoembryonic antigen immune complexes by phospholipase C
Baldo A new screen for anti-inflammatory agents. Estimation of rat serum acute phase α2-macroglobulin levels using rocket immunoelectrophoresis
张学庸 et al. Use of MG series monoclonal antibodies in the diagnosis and experimental targeting therapy of gastric cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2318231

Country of ref document: CA

Ref country code: CA

Ref document number: 2318231

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 539876

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999917293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09600413

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999917293

Country of ref document: EP